Publications

Se­lec­ted pub­lic­a­tions

Hakanpaa L, Kiss EA, Jacquemet G, Miinalainen I, Lerche M, Guzmán C, Mervaala E, Eklund L, Ivaska J, Saharinen P. Targeting β1-integrin inhibits vascular leakage in endotoxemia. Proc Natl Acad Sci U S A. 2018 Jun 25.

Eklund L, Kangas J, Saharinen P. Angiopoietin-Tie signaling in the cardiovascular and lymphatic systems. Clinical Science. 1:87-103, 2017.

Lampinen A, Virman J, Bono P, Luukkaala T, Sunela K, Kujala P, Saharinen P, Kellokumpu-Lehtinen P-L. Novel angiogenesis markers as long-term prognostic factors in renal cell cancer patients. Clin Genitourinary Cancer, 15:e15-e24, 2017.

Korhonen E, Lampinen A, Giri H, Anisimov A, Kim M, Allen B, Fang S, D’Amico G, Sipilä T, Lohela M, Strandin T, Vaheri, Ylä-Herttuala S, Koh GY, McDonald DM, Alitalo K and Saharinen P. Tie1 controls angiopoietin function in vascular remodeling and inflammation. J Clin Invest. August 22, 2016.

Rautiola J, Lampinen A, Mirtti T, Ristimäki A, Joensuu H, Bono P, Saharinen P. Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma. PLoS One. 11(4):e0153745, 2016.

Saharinen P, Ivaska J. Blocking integrin inactivation as an anti-angiogenic therapy. EMBO J. 34:1293-5, 2015.

Hakanpaa L, Sipila T, Leppanen VM, Gautam P, Nurmi H, Jacquemet G, Eklund L, Ivaska J, Alitalo K, Saharinen P. Endothelial destabilization by angiopoietin-2 via integrin β1 activation. Nature Commun 6: 5962, 2015.